Yao Yu

Peer-Reviewed Articles

1. Hahn AW, Manyam GC, Chapin BF, Zhang M, Yu Y, Pettaway CA, Chery L, Pisters LL, Ward JF, Gregg JR, Papadopoulos J, Kamat AM, Lozano M, Hoang A, Broom B, Wang X, Huff CD, Logothetis CJ, Troncoso P, Pilié PG, Davis JW. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int. e-Pub 2024. PMID: 38837608.
2. Xu A, Liu M, Huang MF, Zhang Y, Hu R, Gingold JA, Liu Y, Zhu D, Chien CS, Wang WC, Liao Z, Yuan F, Hsu CW, Tu J, Yu Y, Rosen T, Xiong F, Jia P, Yang YP, Bazer DA, Chen YW, Li W, Huff CD, Zhu JJ, Aguilo F, Chiou SH, Boles NC, Lai CC, Hung MC, Zhao Z, Van Nostrand EL, Zhao R, Lee DF. Rewired m6A epitranscriptomic networks link mutant p53 to neoplastic transformation. Nat Commun 14(1):1694, 2023. e-Pub 2023. PMID: 36973285.

Other Articles

1. Ana M. Aparicio ORCID logo ; Rebecca S. S. Tidwell ORCID logo ; Shalini S. Yadav ORCID logo ; Jiun-Sheng Chen ORCID logo ; Miao Zhang ORCID logo ; Jingjing Liu ORCID logo ; Shuai Guo ORCID logo ; Patrick G. Pilie ORCID logo ; Yao Yu ORCID logo ; Xingzhi Song ORCID logo ; Haswanth Vundavilli ORCID logo ; Sonali Jindal ORCID logo ; Keyi Zhu ORCID logo ; Paul V. Viscuse ORCID logo ; Justin M. Lebenthal ORCID logo ; Andrew W. Hahn ORCID logo ; Rama Soundararajan ORCID logo ; Paul G. Corn ORCID logo ; Amado J. Zurita ORCID logo ; Sumit K. Subudhi ORCID logo ; Jianhua Zhang ORCID logo ; Wenyi Wang ORCID logo ; Chad Huff ORCID logo ; Patricia Troncoso ORCID logo ; James P. Allison ORCID logo ; Padmanee Sharma ORCID logo ; Christopher J. Logothetis A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer(1557-3265), 2024.